The most common viral cause of GBS is CMV. CMV is part of the herpesviridae family and is common in the general population where primary infection leads to lifelong latency of the virus in endothelial cells, smooth muscle cells, fibroblasts, and monocytes. 8, 9 While CMV presents as a relatively benign febrile illness in the immunocompetent host, it is a significant contributor to mortality and morbidity in immunosuppressed individuals, including solid organ transplant recipients. 8 In particular, patients who are seronegative for CMV infection who receive a donor organ from a seropositive donor (D+/R− status)
have a high risk of developing CMV disease due to their immunosuppressive medication regime compounded by the potential for reactivation of a latent virus within the allograft. 8 While
anti-viral prophylaxis is widely used in solid organ transplant recipients, there is still a significant risk of late-onset infection after discontinuation of prophylaxis, with a 1-year incidence of 19.2%. 10 Cytomegalovirus infection has been associated with GBS in both bone marrow and solid organ transplant recipients. 4, 11 There have been reports of both GBS, and the similar condition chronic inflammatory demyelinating polyneuropathy (CIDP), developing after bone marrow transplant in patients with leukaemia, lymphoma, and breast cancer. [12] [13] [14] This is thought to be due to either immune alteration from treatment regimens or new infection or re-activation with a virus. GBS appears to be rarer in the solid organ transplant population, but has previously been reported in recipients of heart, liver and kidney transplants. 4, 15, 16 Almost all cases of GBS in solid organ transplant recipients have been associated with CMV before or at time of onset and the majority of cases have occurred within one year of transplantation. 4, 16 While it could be hypothesized that renal transplant patients are at risk of CMV-induced GBS because of their immunosuppressive regimens, little is known about the incidence of GBS in this population, and the associated morbidity and mortality. We therefore systematically reviewed all cases of GBS in post-renal transplant patients to identify causative pathogens or triggers and compare management and outcomes.
| ME THODS
We conducted a systematic search of case reports published on the MEDLINE Database from 1965 to July 2018 (20/7/2018). Our search strategy included the keywords "renal transplant" and "Guillain-Barré syndrome". No constraints were placed on date of publication and MESH terms were included. Only papers published in English were considered. Reference lists of papers were scrutinised for new articles.
Full articles were read and assessed for relevance and study eligibility.
Included studies were published case reports of Guillain-Barré syndrome in patients who had undergone renal transplantation surgery prior to developing GBS.
We recorded data pertaining to the patient demographics and their renal transplantation, any associated factors such as medications and infections, management and relevant outcome measures (need for ventilatory support, mortality and residual symptoms). 
| RE SULTS
Our search strategy uncovered 38 manuscripts. Twelve case reports were included based on title and abstract. Another 4 case reports were added from the reference lists of included articles (Figure 1 ).
Sixteen full-text case reports were thus assessed for eligibility for inclusion. One case report was excluded because the patient did not have GBS. Fifteen manuscripts were included in the systematic review.
We identified 17 cases of GBS post-renal transplantation in the 15 manuscripts (Table 1) . 4, 5, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] The majority of cases were in males (81%) and patients who received transplants from deceased donors (87%).
The mean age was 44.7 years (SD 13). The time between transplant and onset of symptoms ranged from 2 days to 10 years (Mean = 720 days).
In 15 cases (88%), an infectious aetiology was postulated as a triggering factor. The most common preceding infection was CMV (80%)
followed by diarrhoeal illness (13%) and EBV (7%). Two cases (12%) did not identify an infectious aetiology and tacrolimus 5 In the population reviewed here, 2 case reports specified that the patient required ventilation, 21, 24 12 patients made a full recovery, and four patients had residual symptoms longterm. 4, 19, 22, 24 These included residual lower limb paresis, walking difficulty, and persistent neurogenic bladder. We identified no cases of mortality from GBS in post-renal transplant patients in the literature.
| D ISCUSS I ON
This systematic review identified CMV as the most common trigger for GBS in the renal transplant population. In the cases of CMV-GBS reviewed here, the time between transplant and onset of GBS symptoms ranged from 27 days to 7 years, which is in line with previous findings that acute CMV infection as well as re-activation and re-infection can trigger GBS. 30 CMV-GBS presents differently to Campylobacter jejuni GBS, which is often associated with the pure motor subtype, axonal neuropathy, anti-ganglioside antibodies, and worse prognosis. 31 In contrast, CMV-GBS patients have been found to be younger, more likely to have sensory defects, and are more likely to present with primary demyelinating disease. 32 CMV-GBS is also associated with better prognosis which could explain why we did not identify any cases of mortality from CMV-GBS in the renal transplant population. 32 Seronegative recipients who receive a kidney from a seropositive donor are at a high risk of developing CMV. In this review, out of the 12 cases of GBS-CMV, 8 cases were in seronegative recipients who received an organ from a seropositive donor, and only 1 case was in a seronegative recipient who received an organ from a seronegative donor. Patients often present with late onset CMV disease following the cessation of antiviral prophylaxis, and this is associated with allograft rejection and mortality. 8 Furthermore, this review establishes CMV as a risk factor for the development of GBS in this population, further adding to the potential mortality and morbidity.
It is however interesting to note that there are only 12 cases of CMV-induced GBS in this population reported in the literature, when the incidence of GBS in the general population who contract CMV is 1 in 1000 (25) . This may be due to under-reporting, or alternatively GBS may be rare in renal transplant patients. A possible explanation is that renal transplant patients may be offered some protection against autoimmune diseases by their immunosuppressive regimen. 28 For example, it has been suggested that mycophenolate mofetil may have the potential to decrease the likelihood of GBS through its action on the humoral immune system. 28 Furthermore, the calcineurin inhibitor Cyclosporine has previously been used to successfully treat CIDP in 19 patients who were resistant to other immunosuppressive treatments including corticosteroids, plasmapharesis, and IVIG, as well as one case of chronic relapsing GBS. 33, 34 This suggests that immunosuppression may be beneficial in both the prevention and treatment of GBS and similar conditions.
However, two cases in this review were not associated with infection, but rather with the use of the calcineurin inhibitors Cyclosporine and Tacrolimus. These medications inhibit lymphocyte proliferation, and may be used to prevent graft rejection in transplant recipients, with Tacrolimus having replaced Cyclosporine as a routinely used agent in many transplant centres. 35 In addition to the cases reviewed here, Cyclosporine has been associated with GBS in a lung transplant recipient 15 and validated in an animal model, 36 and Tacrolimus has been linked with three cases of CIDP. 37 The underlying mechanism is thought to be related to dysimmunity induced by T-cell changes caused by these medications. 37 It is likely that the pathogenesis for GBS varies significantly between patients, and while GBS may be partly explained by molecular mimicry due to antecedent infection, it is not a sufficient cause. It is common that no infectious aetiology is identified, and furthermore only a small proportion of the population who have Campylobacter jejuni or CMV infections develop GBS. 9, 31 Therefore, it is clear that host and environmental factors must modulate the susceptibility of individuals to develop GBS, and that more research is needed to further elucidate the pathogenesis of GBS. 9, 31 While this review establishes CMV infection and calcineurin inhibitor medications as potentially important triggers for GBS in renal transplant patients, this is based on associations reported in the literature, and causation cannot be established.
Further research is needed to elucidate whether there is a true causal relationship.
Given the rarity of cases of GBS in renal transplant patients in the literature, it is difficult to say whether there is any difference in mortality and morbidity between the general population and renal transplant patients who acquire GBS.
| CON CLUS ION
CMV is the most common associated infection in GBS in the post- 
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